Phase 2 N=25 Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematopoietic Engraftment — 17.9 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
Phase 3 N=108 A Study for Leukemia Patients With Life-Threatening Infections
Leukemia
Primary: Number of Participants Alive at Day 30 — 31; 39 Participants
N/A N=100 Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)
COPD · Emphysema · Chronic Bronchitis
Primary: Effective Concentration (EC 50) of GRO Alpha — 1.5; 0.9; 0.6 ng/ml — p=0.05
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
N/A N=65 Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear
White Blood Cells
Primary: Leukocyte Population — 583187; 420345; 738140 Leukocytes
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Phase 2 N=202 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
N/A N=43 Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion
Leukocytosis
Primary: Percent Decrease in White Blood Cell Count in Patient Following Apheresis Procedure — 54.5 % change in subject's WBC count
Phase 2 N=30 Sirolimus for Autoimmune Disease of Blood Cells
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Phase 2 N=171 Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications
Blood Transfusion Complications
Primary: Biomarkers Associated With Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload. — 101; 105; 12; 15 units on a scale (pg/ml)
N/A N=177 Microparticles in Stored RBC as Potential Mediators of Transfusion Complications
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
N/A N=59 Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
Phase 1 N=29 Inactivation of Whole Blood With Mirasol
Focus of Study: Radiolabel Recovery and Survival of RBCs
Primary: Red Blood Cell (RBC) 24-Hour Recovery — 82.51; 91.70 % 24-hour RBC Recovery
N/A N=100 Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute
Primary: Survial Rate at 30 Days — 100; 97 percentage of participants
N/A N=15 Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans
Immunologic Deficiency Syndromes
Primary: Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs) — 691; 749 pg/ml
Phase 3 N=26 Age of Blood in Sickle Cell Transfusion
Sickle Cell Disease
Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051
N/A N=162 Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery
Congenital Heart Disease
Primary: 12 Hour Plasma Interleukin (IL)-6 to IL-10 Ratio — 8.9; 3.8 ratio
N/A N=33 An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System
Device Validation of In-vivo Performance
Primary: Number of Participants With Success of RBC's in Vivo Recovery After 42-day Storage — 23 Participants
N/A N=310 Evaluation of Trima Version 7.0 Platelets in 100% Plasma
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 92; 93; 93; 1 Participants
N/A N=335 Evaluation of Trima Version 7.0 Platelets in PAS
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 93; 93; 93; 0 Participants
N/A N=18 Role of Infected Blood Dendritic Cells in Heart Disease Risk
Chronic Periodontitis
Primary: Frequency of Blood Dendritic Cells From Baseline — 12; 14 % MFI
Phase 2 N=17 Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Metastatic Melanoma
Primary: Percentage of Participants With Overall Response (OR) — 38 percentage of participants
Phase 2 N=4 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
N/A N=10 Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
N/A N=254 Frozen Red Blood Cell Transfusions in Trauma Patients
Blood Loss · Anemia · Trauma
Primary: Tissue Oxygenation — 100.3; 98.2; 98.3 percentage of baseline
Phase 1 N=5 Transfusion of Biotinylated Red Blood Cells
Anemia
Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants